Effects of Novel Platinum Drugs on Cell Death in Ovarian Cancer Cells
Author Information
Author(s): CF O'Neill, MG Ormerod, D Robertson, JC Titley, Y Cumber-Walsweer, LR Kelland
Primary Institution: Cancer Research Campaign Centre for Cancer Therapeutics, The Institute of Cancer Research
Hypothesis
The study investigates whether two novel platinum analogues induce apoptosis in human ovarian carcinoma cells.
Conclusion
The trans analogue JM335 induces apoptosis more rapidly than the cis analogue JM149, but at high concentrations, JM335 leads to non-apoptotic cell death.
Supporting Evidence
- JM149 induced apoptosis across a range of concentrations.
- JM335 failed to cause apoptosis at 10 x IC50.
- JM335 showed a faster rate of apoptosis induction compared to JM149.
- At equitoxic concentrations, levels of platinum bound to DNA were similar for both drugs.
Takeaway
This study shows that two new cancer drugs can kill ovarian cancer cells, but one works faster than the other, and too much of one can actually stop the cells from dying properly.
Methodology
The study used the SRB assay to measure cytotoxicity and flow cytometry for cell cycle analysis.
Limitations
The study does not specify the long-term effects of the drugs or their efficacy in vivo.
Participant Demographics
The study focused on the CH1 human ovarian carcinoma cell line.
Statistical Information
P-Value
0.03
Statistical Significance
p=0.03
Want to read the original?
Access the complete publication on the publisher's website